Increased sTREM-1 plasma concentrations are associated with poor clinical outcomes in patients with COVID-19. Issue 7 (30th July 2021)

• Record Type: Journal Article
• Authors: de Nooijer, Aline H.; Grondman, Inge; Lambden, Simon; Kooistra, Emma J.; Janssen, Nico A.F.; Kox, Matthijs; Pickkers, Peter; Joosten, Leo A.B.; van de Veerdonk, Frank L.; Derive, Marc; Gibot, Sebastien; Netea, Mihai G.
• Is Part Of: Bioscience reports. Volume 41:Issue 7(2021)
• Publication Date: 2021-07-30
• Subjects: coronavirus disease 2019 (COVID-19) -- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) -- acute respiratory distress syndrome (ARDS) -- inflammation -- sTREM-1 -- mortality; Molecular biology -- Periodicals; Cytology -- Periodicals; 572.8
• DOI: 10.1042/BSR20210940
• Languages: English
• ISSNs: 0144-8463

Abstract

Abstract: Patients with sepsis display increased concentrations of sTREM-1 (soluble Triggering Receptor Expressed on Myeloid cells 1), and a phase II clinical trial focusing on TREM-1 modulation is ongoing. We investigated whether sTREM-1 circulating concentrations are associated with the outcome of patients with coronavirus disease 2019 (COVID-19) to assess the role of this pathway in COVID-19. This observational study was performed in two independent cohorts of patients with COVID-19. Plasma concentrations of sTREM-1 were assessed after ICU admission (pilot cohort) or after COVID-19 diagnosis (validation cohort). Routine laboratory and clinical parameters were collected from electronic patient files. Results showed sTREM-1 plasma concentrations were significantly elevated in patients with COVID-19 (161 [129–196] pg/ml) compared to healthy controls (104 [75–124] pg/ml; P <0.001). Patients with severe COVID-19 needing ICU admission displayed even higher sTREM-1 concentrations compared to less severely ill COVID-19 patients receiving clinical ward-based care (235 [176–319] pg/ml and 195 [139–283] pg/ml, respectively, P = 0.017). In addition, higher sTREM-1 plasma concentrations were observed in patients who did not survive the infection (326 [207–445] pg/ml) compared to survivors (199 [142–278] pg/ml, P <0.001). Survival analyses indicated that patients with higher sTREM-1 concentrations are at higher risk for death (hazard ratio = 3.3, 95%CI: 1.4–7.8). In conclusion, plasma sTREM-1 concentrations are elevated in patients with COVID-19, relate to disease severity, and discriminate between survivors and non-survivors. This suggests that the TREM-1 pathway is involved in the inflammatory reaction and the disease course of COVID-19, and therefore may be considered as a therapeutic target in severely ill patients with COVID-19.